Longevity & AgingScribe Therapeutics Silences Heart Disease Gene Without Cutting DNA
Biotech company Scribe Therapeutics presented preclinical data showing a new gene-editing approach that lowers LDL cholesterol risk by silencing the PCSK9 gene — without permanently altering DNA. Their ELXR platform uses epigenetic silencing, essentially turning down a harmful gene rather than cutting it out. In non-human primates, a single treatment sustained cholesterol-lowering effects for nearly 18 months. The system also includes a built-in safety mechanism that reduces off-target editing by 10 to 100 times compared to earlier CRISPR tools. If this translates to humans, it could replace daily cholesterol medications with rare, long-lasting treatments — a significant shift in how cardiovascular disease, the world's leading killer, is managed and prevented over a lifetime.
